SCHEMBL1342875

SCHEMBL1342875

COc1ccccc1Oc1ccccc1NC(=O)CC(=O)Nc1nc(CC(=O)O)c(Sc2ncc[nH]2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
CASP1 P29466 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MPO P05164 1/20 0.41
POLB P06746 2/20 0.41
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 3/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 2/20 0.38
ALOX12 P18054 1/20 0.38
RORC P51449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341328 0.93 TSHR (0.38) TSHRCASP1HSD17B10MPOPOLB
SCHEMBL1342957 0.92 CSNK1D (0.39) TSHRCASP1HSD17B10MPOPOLB
SCHEMBL1341907 0.88 TSHR (0.40) TSHRCASP1HSD17B10MPOPOLB
SCHEMBL1342834 0.87 TSHR (0.38) TSHRCASP1HSD17B10MPOPOLB
SCHEMBL1340461 0.86 GCK (0.45) TSHRPOLBGAASMN1; SMN2KDM4E
SCHEMBL1340654 0.85 GCK (0.37) TSHRCASP1HSD17B10MPOPOLB
SCHEMBL1341896 0.84 GAA (0.44) TSHRHSD17B10POLBGAASMN1; SMN2
SCHEMBL2650867 0.84 POLB (0.38) TSHRCASP1HSD17B10MPOPOLB
SCHEMBL1342879 0.83 NPC1 (0.36) TSHRCASP1HSD17B10MPOPOLB
SCHEMBL1341904 0.82 TSHR (0.41) TSHRCASP1HSD17B10MPOPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 TSHR 2745/4885CASP1 1541/4885HSD17B10 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.